BioSpace News Archive

Drug Development

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Limited announced that it has entered into a clinical trial collaboration and supply agreement with MSD, through a subsidiary, to evaluate eftilagimod alfa in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® and chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in a pivotal Phase III trial.

June 2, 2024
·
6 min read
Biotech Bay

Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer

Innovent Biologics, Inc. delivered two oral presentations of its first-in-class anti-CLDN18.2/CD3 bispecific antibody for the treatment of advanced pancreatic cancer and gastric or gastroesophageal tumors at the 2024 American Society of Clinical Oncology Annual Meeting from clinical data of a Phase I study.

June 2, 2024
·
9 min read